Who Paid My Doc
Murad Alam
MOHS-Micrographic Surgery Chicago, IL Medical Doctor
NPI 1578553822 CMS profile 252384
680 N Lake Shore Dr, Suite 1000, Chicago, IL 60611
General payments
$1,066
Research payments
$1,252
Ownership & investment interest
$0
Research they led as principal investigator
$5,000
Through program year 2025, Murad Alam of Chicago, IL is reported in the CMS Open Payments database as having received $1,066 across 13 general payments and $1,252 in research payments paid to them. Separately, studies naming them as principal investigator received $5,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 57th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $33 | 1 | |
| 2024 | General | $566 | 6 | |
| 2023 | General | $108 | 1 | |
| 2022 | General | $295 | 2 | |
| 2021 | General | $23 | 1 | |
| 2020 | General | $25 | 1 | |
| 2020 | Research | $680 | 1 | |
| 2019 | General | $16 | 1 | |
| 2019 | Research | $572 | 2 |
Beside peers
- Murad Alam
- MOHS-Micrographic Surgery median
- Middle half of MOHS-Micrographic Surgery
- National median
In program year 2025, general payments to Murad Alam were reported at $33. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.
Show as a table
| Year | Murad Alam | MOHS-Micrographic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $16 | $316 | $106–$785 | $163 |
| 2020 | $25 | $162 | $68–$412 | $114 |
| 2021 | $23 | $243 | $87–$654 | $132 |
| 2022 | $295 | $300 | $102–$887 | $149 |
| 2023 | $108 | $364 | $125–$1,010 | $160 |
| 2024 | $566 | $445 | $142–$1,108 | $164 |
| 2025 | $33 | $465 | $145–$1,066 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
1,246
Drug cost
$12,197
Branded share of claims
0.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Doxycycline Hyclate | Generic | 562 | $3,767 | |
| Minocycline Hcl | Generic | 254 | $1,904 | |
| Gentamicin Sulfate | Generic | 47 | $1,517 | |
| Ketoconazole | Generic | 67 | $1,030 | |
| Imiquimod | Generic | 23 | $728 | |
| Fluocinonide | Generic | 18 | $701 | |
| Mupirocin | Generic | 83 | $576 | |
| Triamcinolone Acetonide | Generic | 55 | $403 | |
| Clindamycin Phosphate | Generic | 11 | $371 | |
| Clobetasol Propionate | Generic | 18 | $292 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 103 billing codesPaid by Medicare
$1,453,660
Medicare patients
1,208
Services billed
7,857
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 60% | |
| Arthritis | 38% | |
| Ischemic heart disease | 26% | |
| Cancer | 21% | |
| Diabetes | 18% | |
| Chronic kidney disease | 17% | |
| Osteoporosis | 17% | |
| Atrial fibrillation | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 | Office | 81 | 90 | $27,877 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 19 | 36 | $22 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other MOHS-Micrographic Surgery in Illinois
Scott Zahner
MOHS-Micrographic Surgery · Hinsdale, IL
Melanie Zahner
MOHS-Micrographic Surgery · Hinsdale, IL
Kelly Park
MOHS-Micrographic Surgery · Northbrook, IL
Owen Kramer
MOHS-Micrographic Surgery · Elmhurst, IL
Todd Johnson
MOHS-Micrographic Surgery · Chicago, IL
Simon Yoo
MOHS-Micrographic Surgery · Chicago, IL
Related records
MOHS-Micrographic Surgery in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All MOHS-Micrographic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.